Inovio Pharmaceuticals(US:INO) TMX Newsfile·2026-03-31 13:31Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding the company's product development and regulatory prospects [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Inovio to contact them for discussing legal options, particularly for those who purchased securities between October 10, 2023, and December 26, 2025 [1]. - There is an April 7, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action against Inovio [2]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [4]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 for recurrent respiratory papillomatosis but indicated that the company did not provide sufficient information for accelerated approval [5]. - Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share following the FDA's announcement [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].